The Medical Letter on Drugs and Therapeutics
Belatacept (Nulojix) for Prevention of Renal Transplant Rejection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved belatacept (bel at´ a sept; Nulojix – Bristol-Myers Squibb) for prevention of organ rejection in adult patients receiving a kidney transplant.

STANDARD TREATMENT — Maintenance of immunosuppression after renal transplantation can prevent acute rejection and long-term loss of the renal graft. The oral calcineurin inhibitors tacrolimus (Prograf) and cyclosporine (Neoral, and others) are typically used prophylactically for this purpose. Calcineurin inhibitors can cause hypertension and metabolic abnormalities including glucose intolerance, and chronic use has been associated with nephrotoxicity leading to graft failure. Monitoring of trough serum concentrations is required in patients taking cyclosporine or tacrolimus.

MECHANISM OF ACTION — Activated T-cells (lymphocytes) are a major contributor to immunologic rejection. Belatacept is a selective ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Belatacept (Nulojix) for Prevention of Renal Transplant Rejection
Article code: 1379c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian